Michael Halvonik, MD
Pulmonary Disease · Cincinnati, OHNPI 1538249404
Payments from drug & device makers
Across 666 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$1K
- Sanofi$583
- Takeda Pharmaceuticals U.S.A., Inc.$438
- Grifols USA, LLC$419
- plus $2K from 28 others
What the payments were for
- Food & beverage$9,985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 98 | $2,891 |
| GSK | 195 | $2,165 |
| Boehringer Ingelheim | 96 | $1,134 |
| Sanofi | 48 | $583 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $438 |
| Grifols USA, LLC | 33 | $419 |
| Regeneron Healthcare Solutions, Inc. | 33 | $374 |
| Amgen | 16 | $264 |
| Inogen, Inc. | 17 | $191 |
| Mylan Specialty L.p. | 11 | $168 |
| Philips North America LLC | 9 | $143 |
| Genentech USA, Inc. | 8 | $140 |
| Electromed, Inc. | 12 | $140 |
| Sunovion Pharmaceuticals Inc. | 11 | $130 |
| Insmed, Inc. | 6 | $115 |
| United Therapeutics Corporation | 4 | $80 |
| Merck | 5 | $74 |
| Mallinckrodt Hospital Products Inc. | 4 | $73 |
| Covis Pharma GmbH | 3 | $58 |
| Novartis | 4 | $56 |
| Pfizer | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Nabriva Therapeutics, PLC | 2 | $30 |
| Paratek Pharmaceuticals, Inc. | 2 | $27 |
| Circassia Inc. | 2 | $26 |
| Baxter Healthcare | 1 | $25 |
| Gilead | 2 | $24 |
| Astellas Pharma US Inc | 2 | $23 |
| Fisher & Paykel Healthcare Inc | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,985 in reported general payments places this provider in the 75th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 680 | $698,945 |
| OfevNintedanib Esylate | 41 | $520,358 |
| Pirfenidone | 44 | $239,451 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 259 | $196,731 |
| Breo ElliptaFluticasone/Vilanterol | 212 | $124,889 |
| Spiriva RespimatTiotropium Bromide | 123 | $117,067 |
| NucalaMepolizumab | 13 | $55,672 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $21,102 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $18,296 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $17,968 |
| DuleraMometasone/Formoterol | 23 | $14,404 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $14,288 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 668 | $14,015 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 93 | $13,759 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 53 | $11,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta | $2,165 | $915,233968 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $1,134 | $669,681211 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,891 | $223,037321 claims |
| MerckDulera | $74 | $14,40423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cincinnati
- Bruce CorserCincinnati$8.2M
- Jean ElwingCincinnati$2.4M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Mohammad SheattCincinnati$405K
- Robert BurkesCincinnati$299K
- Arun JoseCincinnati$287K
- Bruce TrapnellCincinnati$153K
- Rachel FootCincinnati$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.